Precigen (NASDAQ:PGEN) Shares Gap Up After Analyst Upgrade

Precigen, Inc. (NASDAQ:PGEN)’s share price gapped up before the market opened on Thursday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The stock had previously closed at $3.10, but opened at $4.07. Precigen shares last traded at $3.9670, with a volume of 10,133,553 shares changing hands.

A number of other analysts have also recently issued reports on the company. Citizens Jmp lifted their price objective on Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. HC Wainwright lifted their price target on Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Finally, Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.50.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

Hedge Funds Weigh In On Precigen

Hedge funds have recently bought and sold shares of the business. Patient Capital Management LLC raised its holdings in Precigen by 62.6% during the third quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after buying an additional 10,192,107 shares in the last quarter. State Street Corp boosted its stake in shares of Precigen by 141.1% during the 4th quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after acquiring an additional 6,335,033 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Precigen by 15.9% during the 4th quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock worth $18,653,000 after acquiring an additional 613,340 shares in the last quarter. Occam Crest Management LP increased its holdings in shares of Precigen by 29.6% during the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after acquiring an additional 799,339 shares during the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new position in shares of Precigen during the 4th quarter valued at about $12,540,000. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Price Performance

The stock has a 50 day moving average of $4.08 and a two-hundred day moving average of $3.98. The company has a debt-to-equity ratio of 4.46, a quick ratio of 3.95 and a current ratio of 3.09. The firm has a market capitalization of $1.30 billion, a P/E ratio of -2.74 and a beta of 1.10.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The firm had revenue of $4.57 million during the quarter, compared to analysts’ expectations of $8.29 million. Sell-side analysts predict that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.